Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cells armed to hunt down hidden leukemia

NCT ID NCT07270978

Recruiting now Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new cell therapy for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have small amounts of cancer cells after standard treatment. The therapy uses the patient's own blood cells, armed with a special antibody to target and kill cancer cells. Up to 23 participants will receive up to 4 cycles of weekly infusions, followed by standard chemotherapy. The main goal is to check safety and see if the treatment can clear the remaining disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CD33Bi-armed immune cells (a type of cell therapy)
What this could lead to
If successful, this could offer a new way to eliminate remaining cancer cells in AML or MDS patients, potentially improving long-term outcomes.
What could go wrong
This is an early Phase 1 trial with only 23 participants, so safety and effectiveness are not yet proven. The treatment may cause side effects or fail to clear the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes myelodysplastic/myeloproliferative disease myelodysplastic/myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM

Contacts and locations

Locations

  • University of Virginia

    RECRUITING

    Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.